(Q24236324)

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Peripheral action of spironolactone: plethysmographic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Treatment of hypertension with spironolactone. Double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Spironolactone and hydrochlorothiazide in normal-renin and low-renin essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Renin concentrations and effects of propranolol and spironolactone in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Efficacy of low-dose spironolactone in subjects with resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Clinical and biochemical effects of spironolactone administered once daily in primary hypertension. Multicenter Sweden study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Renin levels and spironolactone treatment in general practice: similar blood pressure lowering effect of spironolactone in low and normal renin patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Efficacy and tolerance of spironolactone in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Spironolactone and gastrointestinal bleeding: a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Spironolactone and risk of upper gastrointestinal events: population based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

Spironolactone in hypertensive patients. Oligemic and antihypertensive effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

7 January 2021

Treatment of arterial hypertensive disease with diuretics. I. Effects on blood pressure of bendroflumethiazide, potassium chloride, and spironolactone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

7 January 2021

Treatment of arterial hypertensive disease with diuretics. V. Spironolactone, an aldosterone antagonist

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

7 January 2021

The syndrome of essential hypertension and suppressed plasma renin activity. Normalization of blood pressure with spironolactone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

7 January 2021

Spironolactone and hydrochlorothiazide in essential hypertension. Blood pressure response and plasma renin activity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

7 January 2021

Controlled treatment of primary hypertension with propranolol and spironolactone. A crossover study with special reference to initial plasma renin activity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

7 January 2021

The effects of spironolactone and chlorthalidone on arterial pressure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

7 January 2021

Are angiotensin converting enzyme inhibition and aldosterone antagonism equivalent in hypertensive patients over fifty?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

7 January 2021

Effect of Spironolactone in Hypertensive Patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

7 January 2021

Aldosterone antagonist therapy in resistant hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

7 January 2021

The effect of spironolactone (Aldactone) and methyldopa in low and normal renin hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

7 January 2021

The effects of four months' treatment with spironolactone on systemic blood pressure, cardiac output and plasma renin activity in hypertensive patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

7 January 2021

Treating resistant hypertension with a neglected old drug

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

7 January 2021

The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

7 January 2021

Spironolactone in resistant hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008169.PUB2

7 January 2021